# Evidence for the evolving role of neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer.

**Tumor:** CPNM (cáncer de pulmón)
**Autores:** Hansen T, Hill J, Tincknell G et al
**Revista:** Explor Target Antitumor Ther (2024)
**PMID:** 39465010 | **PMCID:** PMC11502072
**DOI:** [10.37349/etat.2024.00273](https://doi.org/10.37349/etat.2024.00273)
**Fuente:** PubMed Central (open access)

## Relevancia
CPNM resecable tras quimio-inmunoterapia neoadyuvante (CheckMate-816, NADIM, KEYNOTE-671): downstaging mediastínico (ypN0/N1), tasas de pCR ganglionar y supervivencia. Paralelo importante con mama: la conversión nodal patológica predice EFS/OS y orienta la extensión de la disección ganglionar.

## Abstract
The treatment of early-stage non-small cell lung cancer (NSCLC) is becoming increasingly complex. Standard of care management for the past decade has been adjuvant chemotherapy following curative intent resection regardless of nodal status or tumour profile. With the increased incorporation of immunotherapy in NSCLC, especially in the locally advanced, unresectable, or metastatic settings, multiple studies have sought to assess its utility in early-stage disease. While there are suboptimal responses to neoadjuvant chemotherapy alone, there is a strong rationale for the use of neoadjuvant immunotherapy in tumour downstaging, based upon the concept of enhanced T cell priming at the time of a high tumour antigen burden, and demonstrated clinically in other solid tumours, such as melanoma. In the NSCLC cancer setting, currently over 20 combinations of chemoimmunotherapy in the neoadjuvant and perioperative setting have been studied with results variable. Multiple large phase III studies have demonstrated that neoadjuvant chemoimmunotherapy combinations result in significant advances in pathological response, disease free and overall survival which has led to practice change across the world. Currently, combination immunotherapy regimens with novel agents targeting alternate immunomodulatory pathways are now being investigated. Given this, the landscape of treatment in resectable early-stage NSCLC has become increasingly complex. This review outlines the literature of neoadjuvant and perioperative immunotherapy and discusses its potential benefits and complexities and ongoing considerations into future research.

## Acceso
Disponible en PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11502072/

---
*Datos de PubMed. Citar: doi 10.37349/etat.2024.00273*
